Showing 15 posts of 749 posts found.


Sanofi’s RSV drug sees Phase III clinical trial success

April 26, 2021
Sales and Marketing AstraZeneca, Sanofi

Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial …


AstraZeneca drug evaluated in nine eosinophilic diseases

April 23, 2021
Medical Communications AstraZeneca

AstraZeneca announced on Thursday that the first patients had been dosed in the Phase III Fasenra (benralizumab) clinical trial in …


Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …


Forxiga accepted for use within NHS Scotland for chronic heart failure

April 14, 2021
Research and Development AstraZeneca, nhs scotland

AstraZeneca have announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) …

AstraZeneca sign

AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19

April 13, 2021
Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news

AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …


AstraZeneca halt paediatric trial of COVID-19 vaccine amid blood clot probe

April 7, 2021
Research and Development AstraZeneca, COVID-19, Vaccine

AstraZeneca has halted the trial of its COVID-19 vaccine on children aged between 6 and 17, while regulators investigate a …

AstraZeneca sign

AstraZeneca vaccine found to be 3% less effective after further trial analysis

March 25, 2021
AstraZeneca, AstraZeneca vaccine, COVID-19, COVID-19 vaccine, Vaccine

AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms …

AstraZeneca COVID-19 vaccine deemed “safe and effective” by EMA

March 19, 2021
Medical Communications AstraZeneca, COVID-19, EMA, Vaccine

AstraZeneca’s COVID-19 vaccine has been cleared for continued use by the EMA following an investigation into the reports of 37 …

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

AstraZeneca leukaemia treatment recommended for NHS use

March 18, 2021
AstraZeneca, NHS

AstraZeneca has announced today that its oral targeted cancer therapy, Calquence (acalabrutinib), has been recommended by NICE for routine use …


AstraZeneca vaccine suspended in 11 European countries

March 16, 2021
Manufacturing and Production AstraZeneca

Blood clot fears have caused 11 European countries to suspend the use of the Oxford-AstraZeneca vaccine. France, Germany, Italy, and …


Netherlands suspends AstraZeneca vaccine despite safety assurances

March 15, 2021
Medical Communications, Sales and Marketing AstraZeneca, COVID-19, EMA, EU, WHO

The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine amid concerns it may cause …


AstraZeneca wins US court ruling on Symbicort patent claims

March 3, 2021
Research and Development AstraZeneca, Symbicort, law

A US district court has ruled in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, AstraZeneca …

Single Pfizer or AstraZeneca vaccine dose drastically reduces COVID-19 hospitalisations in over-80s

March 2, 2021
Manufacturing and Production AstraZeneca, COVID-19, COVID-19 vaccine, Pfizer, Vaccine

A single dose of the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine reduces UK hospitalisations in over-80s by 80%, a Public Health …


AstraZeneca to withdraw Imfinzi US indication for bladder cancer

February 22, 2021
Sales and Marketing AstraZeneca, Imfinzi

AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …

Latest content